Mode
Text Size
Log in / Sign up

CABU-EICO intervention bundle reduced Watch-group antibiotic use from 26.8% to 17.1% in community settingsCommunity education helps reduce use of high-risk antibiotics

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that the CABU-EICO intervention bundle significantly reduced Watch-group antibiotic use in community settings.

This cluster-randomized controlled trial was conducted in community-based settings, including health centers, private clinics, pharmacies, and informal vendors, in Nanoro, Burkina Faso, and Kimpese, DR Congo. The study targeted community-level healthcare providers and the populations they served. The study enrolled 5532 patients at baseline, with 4898 patients remaining for the post-intervention analysis. The study design allowed for a stronger inference of causality compared to observational studies.

The intervention, known as CABU-EICO, was a co-created bundle consisting of community health education campaigns and educational and feedback sessions with healthcare providers. This bundle specifically integrated the WHO AWaRe Antibiotic Book guidance into the provider training and community outreach. The control group received standard care without the specific CABU-EICO intervention components.

The primary outcome was the baseline-to-post-intervention changes in Watch-group antibiotic use, which were cluster-adjusted and offset for healthcare utilization. In the intervention group, Watch-group antibiotic use decreased from 26.8% to 17.1%. In contrast, the control group saw an increase from 13.4% to 21.2%. The results showed an adjusted prevalence ratio of 0.33 (95% CI 0.14-0.78).

Secondary outcomes included patient management scores for five common, well-defined infections. The results for these scores showed minimal changes, indicating that the reduction in Watch-group antibiotic use did not negatively impact the perceived management of common infections. No specific effect sizes or p-values were reported for these secondary outcomes.

Regarding safety and tolerability, the study did not report any specific adverse events, serious adverse events, or discontinuations. The data do not provide specific information on the tolerability of the intervention for the providers or the patients.

While this study provides evidence for reducing high-risk antibiotic use, it is important to note that the primary outcome is a change in the prevalence of use rather than a direct clinical outcome for the patients. Furthermore, the study specifically focuses on the reduction of Watch-group antibiotics, not all antibiotics. The findings are specific to the community-based settings in the regions of Burkina Faso and DR Congo.

Methodological limitations were not reported. However, the study's focus on a specific geographical and cultural context may limit the generalizability of the CABU-EICO bundle to different healthcare systems. The study also does not provide data on the long-term sustainability of these behavioral changes beyond the 9-month follow-up period.

For clinical practice, these results suggest that a behavioral intervention bundle involving both provider education and community-level messaging can successfully reduce the use of Watch-group antibiotics. This could be a viable strategy for antimicrobial stewardship in resource-limited settings. Questions remain regarding the long-term impact on clinical outcomes for patients and the scalability of the CABU-EICO model to other regions or different types of healthcare facilities.

How this fits prior evidence

How this fits prior evidence This study addresses a gap in evidence regarding the impact of behavioral interventions on antimicrobial stewardship in community settings. While previous evidence has established that antibiotic exposure is associated with an increased risk of developing Irritable Bowel Syndrome, this study focuses on reducing the use of high-risk Watch-group antibiotics. The finding of a significant reduction in Watch-group antibiotic use from 26.8% to 17.1% provides a specific strategy for managing antibiotic stewardship in community-based healthcare environments.

Antibiotic resistance is a global health concern because it makes common infections harder to treat. When certain high-risk antibiotics are used too often or incorrectly, it can lead to the development of resistant bacteria. This study focused on a specific group of antibiotics known as the Watch group. These are medicines that are particularly important to keep available for serious infections. Reducing their unnecessary use is a key goal for health experts worldwide.

Researchers conducted a cluster-randomized controlled trial in two locations: Nanoro, Burkina Faso, and Kimpese, DR Congo. The study involved a large group of patients seen at various locations, including health centers, private clinics, pharmacies, and even informal vendors. The researchers wanted to see if a specific educational program could change how healthcare providers prescribe antibiotics. The intervention was a bundle of community health education campaigns and feedback sessions for providers, based on World Health Organization guidelines.

The results showed a significant change in how antibiotics were used. In the group that received the educational intervention, the use of Watch-group antibiotics dropped from 26.8% to 17.1%. In contrast, the use of these antibiotics increased in the control group, rising from 13.4% to 21.2%. This suggests that the educational program was effective at changing provider behavior. Additionally, the study looked at how well patients were managed for five common infections. These scores showed minimal changes, meaning the education did not negatively affect the quality of care provided to patients.

While the results are promising, there are important details to consider. The study specifically measured the use of the Watch-group antibiotics, not all types of antibiotics. Furthermore, the primary outcome was a change in the frequency of use among providers, not a direct measurement of clinical outcomes like recovery rates or cure rates for the patients. Because the study did not report specific safety data or adverse events, it is difficult to comment on the safety profile of the intervention itself.

For patients and the public, this research shows that targeted education for healthcare providers can successfully reduce the use of high-risk antibiotics. It suggests that community-based programs can be an effective way to manage antibiotic use without compromising the quality of patient care. However, because this was a single study in specific regions, it does not mean that these results will be identical in every country or clinic. It provides a helpful model for how to address antibiotic stewardship in community settings.

What this means for you:
A community-based education program successfully reduced the use of high-risk antibiotics without affecting patient care.

Study Details

Study typeRct
Sample sizen = 5,532
EvidenceLevel 2
Follow-up9.0 mo
PublishedOct 2026
View Original Abstract ↓
BACKGROUND: Increasing Watch-group antibiotic use might be contributing to antimicrobial resistance burden in sub-Saharan Africa. We evaluated the effects of a community-based, co-created intervention bundle targeting all community-level health-care providers and the communities they serve on Watch-group antibiotic use and patient management. METHODS: In a cluster-randomised, controlled trial in Nanoro, Burkina Faso, and Kimpese, DR Congo, villages or neighbourhoods with at least 500 inhabitants and at least one community-level or primary-care provider functioning as the main medicine dispenser for the population were randomly allocated (1:1) to intervention or control groups, using the RAND function in Excel. Over 9 months, three intervention rounds consisted of community health education campaigns and educational and feedback sessions with providers, introducing WHO AWaRe (Access, Watch, Reserve) Antibiotic Book guidance for infections with highest antibiotic use. We measured baseline-to-post-intervention changes in Watch-group antibiotic use through repeated patient surveys (100 per provider per village), cluster-adjusted and offset for health-care utilisation (primary outcome), and patient management scores for five common, well defined infections through simulated patient visits (secondary outcome). Providers with fewer than 20 completed surveys at baseline or post-intervention were excluded. Field workers conducting patient surveys and simulated patient visits were masked to group assignment. CABU-EICO was registered on ClinicalTrials.gov (NCT05378880). FINDINGS: 44 villages or neighbourhoods (22 each in Nanoro and Kimpese) were enrolled and randomly assigned to intervention (11 each in Nanoro and Kimpese) or control (11 each in Nanoro and Kimpese) groups. At baseline (Oct 26, 2022, to March 13, 2023), 5532 patients were surveyed (3558 in Nanoro and 1974 in Kimpese). Post-intervention (Nov 6, 2023, to April 3, 2024), 4898 patients (3180 in Nanoro and 1718 in Kimpese) were surveyed. Patients were surveyed at 32 health centres (18 intervention and 14 control), 31 private clinics (15 intervention and 16 control), 45 pharmacies (25 intervention and 20 control), and 41 informal vendors (22 intervention and 19 control). A total of 1092 simulated patient visits were completed across both periods. The weighted prevalence of Watch-group antibiotic use decreased from 26·8% (95% CI 8·8-44·8) to 17·1% (7·7-26·5) in the intervention group and increased from 13·4% (4·8-22·0) to 21·2% (8·9-33·5) in the control group; the adjusted prevalence ratio for use of Watch-group antibiotics was 0·33 (95% CI 0·14-0·78). Changes in patient management scores were minimal. INTERPRETATION: The behavioural intervention bundle was associated with a substantial reduction in Watch-group antibiotic use and no negative effect on patient management, highlighting the potential of antibiotic use improvements across health-care providers. Reduced community-level use of broad-spectrum antibiotics could help slow community-acquired pathogens' increasing resistance to clinically important antibiotics. FUNDING: The Joint Programming Initiative on Antimicrobial Resistance Research and Research Foundation-Flanders. TRANSLATIONS: For the French translation of the abstract see Supplementary Materials section.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.